Navigation Links
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
Date:6/11/2015

SAN DIEGO, June 11, 2015 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the treatment of specified diseases using Arcturus' UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform. Arcturus will receive an upfront payment, R&D support, and pre-clinical, development and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program. The collaboration brings together Arcturus' expertise and intellectual property in the field of RNA medicines along with Janssen's clinical development, regulatory, and marketing proficiency.

"We are pleased to be collaborating with a top tier pharmaceutical company like Janssen," said Joseph E. Payne, President & CEO of Arcturus Therapeutics. "Arcturus is thrilled to be working together with Janssen to identify an RNA treatment for one of the pharmaceutical industry's most challenging disease targets."

About Arcturus Therapeutics, Inc.

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies – UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.  The company owns unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (34 patents and patent applications, issued in the U.S. and other countries).  The patented UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 


'/>"/>
SOURCE Arcturus Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
2. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
3. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
4. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
5. Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis
6. vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
7. Asia-Pacific Rheumatoid Arthritis Therapeutics Markets 2015-2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
8. Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
9. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
10. GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines
11. Pivotal Therapeutics Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2020)... , ... February 26, 2020 , ... SGF is the ... and personalized fertility care for over two decades. With seven locations in Northern Virginia, ... total to 13 reproductive endocrinologists and 1 reproductive urologist. SGF Fairfax’s lab director recently ...
(Date:2/23/2020)... ... February 23, 2020 , ... ... a three-year accreditation by CARF International, the Commission on Accreditation of Rehabilitation ... services whose mission is to promote quality, value, and optimal outcomes through ...
(Date:2/21/2020)... ... 21, 2020 , ... Nationwide jails are seeing higher rates of incarcerated people ... mental illness is no more likely to commit a crime than anyone else, when ... , They may be experiencing symptoms that lead to these types of crimes. ...
Breaking Medicine Technology:
(Date:2/28/2020)... ... 28, 2020 , ... , Psychics1on1.com is the newest way to connect ... a month, the site has over 3,000 returning customers and now boasts a verified ... now work exclusively from home and online through this amazing new site. This is ...
(Date:2/28/2020)... ... 2020 , ... Segal Trials, a privately held network of ... excited to announce the screening of its first patient for a Phase 2 ... depressive disorder (MDD). , Dr. Rishi Kakar and his clinical research team, at ...
(Date:2/26/2020)... ... February 26, 2020 , ... The epilepsy ... robotic device that helps pinpoint the origin of epileptic seizures on a patient. ... called a Robotized Surgical Assistant, or ROSA. With assistance from the robot, neurosurgeons ...
(Date:2/23/2020)... ... 2020 , ... One of the stars of the long-running ... host of the informational program “Behind The Scenes.” “Behind The Scenes” educates its ... A soon to be aired episode will interview industry professionals about healthy eating ...
(Date:2/21/2020)... ... ... with Bay-Bay Water today announced that the company has launched a new logo. ... part of the ongoing evolution of our company’s brand,” said Osmay Gonzalez, spokesperson of the ... its national reach. , “We have refreshed our logo to reflect who we are today ...
Breaking Medicine News(10 mins):